BioTelemetry Gets FDA Clearance For Its MCOT Patch

BioTelemetry, Inc.

revealed Tuesday that it received the Food and Drug Administration's approval for its next generation Mobile Cardiac Outpatient Telemetry device, the MCOT Patch. According to the company, the MCOT Patch is a four-lead, two-channel system offering the same best-in-class technology as the current MCOT, in a more convenient form factor. BioTelemetry said that the devices, with the help of a proprietary algorithm, provide the most accurate remote arrhythmia detection available on the market. The company added that the new device was created in alliance with Belgium-based IMEC. The company disclosed that the system added proprietary patch technology that it recently acquired from DELTA Danish Electronics, Light and Acoustic. The Company added that the device might be commercially available later in the current year. BioTelemetry's President and CEO, Joseph Capper, commented: "Validated by numerous clinical publications and abstracts, MCOT™ is widely recognized among remote monitoring options as the "gold standard" in terms of sensitivity and accuracy in the detection of arrhythmias such as atrial fibrillation. The MCOT™ Patch incorporates this same unmatched detection capability into a light-weight, easy-to-use patch form factor, which we believe will lead to higher utilization." He added, "Moreover, due to its advanced capabilities and flexible design, our new sensor is also anticipated to have commercially viable applications in other areas of healthcare. The introduction of the new system demonstrates our ongoing commitment to reaching as many patients as possible with our life-saving technology and service." Following the news, shares of the company surged 9.08 percent on Tuesday.